中国普外基础与临床杂志

中国普外基础与临床杂志

脂联素基因 rs2241766 位点多态性与结直肠癌风险相关性的 meta 分析

查看全文

目的 探讨脂联素基因 rs2241766 位点多态性与结直肠癌风险的相关性。 方法 计算机检索 PubMed、Sciencedirect、Embase、Cochrane Database、OVID Medline、Springer Link、EBSCO、中国知网、维普、万方及中国生物医学数据库,筛选脂联素基因 rs2241766 位点多态性与结直肠癌风险相关性的病例对照研究,检索时间为建库至 2017 年 9 月,同时手工查阅检索相似文献及参考文献。由 2 位研究者独立进行文献筛选和资料提取。采用 Review Manager 5.3 软件进行 meta 分析,探索 5 种常见基因模型与结直肠癌发生的关系,计算结果以 OR 值及 95% 置信区间(95% CI)表示。 结果 共纳入文献 10 篇,包括 3 460 例结直肠癌患者和 4 170 例对照。meta 分析结果显示:① 等位基因模型,总体上等位基因模型与结直肠癌的发生有关 [OR总体=1.15,95% CI 为(1.07,1.24),P=0.000 1],白种人中等位基因模型与结直肠癌的发生无关 [OR白种人=1.08,95% CI 为(0.89,1.30),P=0.44],而黄种人中等位基因模型与结直肠癌的发生有关 [OR黄种人=1.16,95% CI 为(1.08,1.26),P=0.000 1]。② 显性基因模型:总体上显性基因模型与结直肠癌的发生有关 [OR总体=1.23,95% CI 为(1.12,1.35),P<0.000 1],白种人中显性基因模型与结直肠癌的发生无关 [OR白种人=1.17,95% CI 为(0.93,1.46),P=0.17],而黄种人中等位基因模型与结直肠癌的发生有关 [OR黄种人=1.24,95% CI 为(1.12,1.37),P<0.000 1]。③ 隐性基因模型:总体[OR总体=1.09,95% CI 为(0.92,1.30),P=0.32]、白种人 [OR白种人=0.77,95% CI 为(0.46,1.28),P=0.31] 和黄种人 [OR黄种人=1.15,95% CI 为(0.95,1.39),P=0.15]中,隐性基因模型与结直肠癌的发生均无关。④ 共显性基因模型:总体上共显性基因模型与结直肠癌的发生有关 [OR总体=1.20,95% CI 为(1.10,1.32),P<0.000 1],白种人中共显性基因模型与结直肠癌的发生无关 [OR白种人=1.25,95% CI 为(0.99,1.58),P=0.06],而黄种人中共显性基因模型与结直肠癌的发生有关 [OR黄种人=1.19,95% CI 为(1.08,1.32),P=0.000 6]。⑤ 超显性基因模型:总体上超显性基因模型与结直肠癌的发生有关 [OR总体=0.83,95% CI 为(0.76,0.91),P<0.000 1],白种人中超显性基因模型与结直肠癌的发生无关 [OR白种人=0.80,95% CI 为(0.63,1.01),P=0.06],而黄种人中超显性基因模型与结直肠癌的发生有关 [OR黄种人=0.84,95% CI 为(0.76,0.93),P=0.000 6]。 结论 脂联素基因 rs2241766 位点多态性与黄种人结直肠癌的发生存在一定的相关性,但与白种人结直肠癌的发生无显著相关性。

Objective To explore the correlation of adiponectin rs2241766 gene polymorphism and colorectal cancer. Methods Case-control studies about correlation of adiponectin rs2241766 gene polymorphisms and colorectal cancer were searched by computer retrieval on PubMed, Sciencedirect, Embase, the Cochrane Database, OVID Medline, Springer Link, EBSCO Database, CNKI, VIP, Wanfang, and Chinese Biomedicine Database, the retrieval time was from inception of database to September 30, 2017. At the same time, collected similar literatures and references by manual retrieval. Two independent researchers took the mask of study selection and data extraction, Review Manager 5.3 software was used on calculation results with the OR value and 95% confidence interval (95% CI), on the condition of 5 kinds of gene models. Results A total of 10 case-control studies were included, including 3 460 cases of colorectal cancer and4 170 controls. Results of meta-analysis showed the effect of 5 kinds of model. ① Allele gene model (G vs T): in general population and Yellow race, allele gene model was related to occurrence of colorectal cancer [ORtotal=1.15, 95% CI was (1.07, 1.24), P=0.000 1; ORYellow race=1.16, 95% CI was (1.08, 1.26), P=0.000 1], but there was no significant difference on relationship between allele gene model and occurrence of colorectal cancer for White [ORWhite=1.08, 95% CI was (0.89, 1.30), P=0.44]. ② Dominant gene model (TG+GG vs TT): in general population and Yellow race, dominant gene model was related to occurrence of colorectal cancer [ORtotal=1.23, 95% CI was (1.12, 1.35), P<0.000 1;ORYellow race=1.24, 95% CI was (1.12, 1.37), P=<0.000 1], but there was no significant difference on relationship between dominant gene model and occurrence of colorectal cancer for White [ORWhite=1.17, 95% CI was (0.93, 1.46), P=0.17]. ③ Implicit gene model (GG vs TT+TG): there was no significant difference on relationship between implicit gene model in 3 kinds of population and occurrence of colorectal cancer [general population: ORtotal=1.09, 95% CI was (0.92, 1.30), P=0.32; White: ORWhite=0.77, 95% CI was (0.46, 1.28), P=0.31; Yellow race: ORYellow race=1.15, 95% CI was (0.95, 1.39), P=0.15]. ④ Codominant gene model (TG vs TT): in general population and Yellow race, codominant gene model was related to occurrence of colorectal cancer [ORtotal=1.20, 95% CI was (1.10, 1.32), P<0.000 1;ORYellow race=1.19, 95% CI was (1.08, 1.32), P=0.000 6], but there was no significant difference on relationship between codominant gene model and occurrence of colorectal cancer for White [ORWhite=1.25, 95% CI was (0.99, 1.58), P=0.06]. ⑤ Superdominant gene model (TT+GG vs TG): in general population and Yellow race, superdominant gene model was related to occurrence of colorectal cancer [ORtotal=0.83, 95% CI was (0.76, 0.91), P<0.000 1;ORYellow race=0.84, 95% CI was (0.76, 0.93), P=0.000 6], but there was no significant difference on relationship between superdominant gene gene model and occurrence of colorectal cancer for White [ORWhite=0.80, 95% CI was (0.63, 1.01), P=0.06]. Conclusion The polymorphism of adiponectin gene rs2241766 is related to the occurrence of colorectal cancer in the Yellow race, but there is no significant correlation in White.

关键词: 结直肠癌; 脂联素; rs2241766 位点; 基因多态性; meta 分析

Key words: colorectal cancer; adiponectin; rs2241766; genetic polymorphism; meta-analysis

引用本文: 李政, 周天义, 贺小会, 谭志辉, 张先林. 脂联素基因 rs2241766 位点多态性与结直肠癌风险相关性的 meta 分析. 中国普外基础与临床杂志, 2018, 25(5): 592-601. doi: 10.7507/1007-9424.201711006 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Ransohoff DF, Sox HC. Clinical practice guidelines for colorectal cancer screening: new recommendations and new challenges. JAMA, 2016, 315(23): 2529-2531.
2. Chandler PD, Buring JE, Manson JE, et al. Association between plasma adiponectin levels and colorectal cancer risk in women. Cancer Causes Control, 2015, 26(7): 1047-1052.
3. Abe Vicente M, Donizetti Silva T, Barão K, et al. The influence of nutritional status and disease on adiponectin and TNF-α; levels in colorectal cancer patients. NutrHosp, 2014, 30(1): 140-146.
4. Tae CH, Kim SE, Jung SA, et al. Involvement of adiponectin in early stage of colorectal carcinogenesis. BMC Cancer, 2014, 14: 811.
5. Inamura K, Song M, Jung S, et al. Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status. J Natl Cancer Inst, 2015, 108(4): djv363.
6. Margulis AV, Pladevall M, Riera-Guardia N, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol, 2014, 6: 359-368.
7. Kaklamani VG, Wisinski KB, Sadim M, et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1(ADIPOR1) genes and colorectal cancer risk. JAMA, 2008, 300(13): 1523-1531.
8. Partida-Pérez M, de la Luz Ayala-Madrigal M, Peregrina-Sandoval J, et al. Association of LEP and ADIPOQ common variants with colorectal cancer in Mexican patients. Cancer Biomark, 2010, 7(3): 117-121.
9. Al Khaldi RM, Al Mulla F, Al Awadhi S, et al. Associations of single nucleotide polymorphisms in the adiponectin gene with adiponectin levels and cardio-metabolic risk factors in patients with cancer. Dis Markers, 2011, 30(4): 197-212.
10. 刘莉. 脂联素及瘦素基因家族与结直肠癌-易感性及疾病进展研究. 武汉: 华中科技大学, 2012.
11. He B, Pan Y, Zhang Y, et al. Effects of genetic variations in the adiponectin pathway genes on the risk of colorectal cancer in the Chinese population. BMC Med Genet, 2011, 12: 94.
12. 张颖, 冯全林, 刘长明, 等. 脂联素及其受体基因多态性与结直肠癌发生的相关性研究. 江苏大学学报(医学版), 2012, 22(4): 336-341.
13. 刘文辉, 李晓玲, 袁萍, 等. 脂联素基因和钙蛋白酶10基因多态性与结直肠癌发生风险的关系. 山东大学学报(医学版), 2014, 52(11): 106-112.
14. Ou Y, Chen P, Zhou Z, et al. Associations between variants on ADIPOQ and ADIPOR1 with colorectal cancer risk: a Chinese case-control study and updated meta-analysis. BMC Med Genet, 2014, 15: 137.
15. Guo X, Liu J, You L, et al. Association between adiponectin polymorphisms and the risk of colorectal cancer. Genet Test Mol Biomarkers, 2015, 19(1): 9-13.
16. 向德森, 张敬, 肖杰, 等. 脂联素基因多态性与结直肠癌发病风险关联性研究. 重庆医学, 2015, 44(25): 3493-3496.
17. 魏丽萍, 蒙广星, 杨锐英. 脂联素的研究进展. 医学综述, 2005, 11(2): 151-153.
18. Song M, Zhang X, Wu K, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res (Phila), 2013, 6(9): 875-885.
19. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev, 2012, 33(4): 547-594.
20. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst, 2005, 97(22): 1688-1694.
21. Kawashima K, Maeda K, Saigo C, et al. Adiponectin and intelectin-1: important adipokine players in obesity-related colorectal carcinogenesis. Int J MolSci, 2017, 18(4): E866.
22. Song M, Gong J, Giovannucci EL, et al. Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer, 2015, 137(1): 154-164.
23. Katira A, Tan PH. Evolving role of adiponectin in cancer-controversies and update. Cancer Biol Med, 2016, 13(1): 101-119.
24. An W, Bai Y, Deng SX, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev, 2012, 21(2): 126-133.
25. Xu XT, Xu Q, Tong JL, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis, 2011, 12(4): 234-244.
26. Li Q, Ma Y, Sang W, et al. Five common haplotype-tagging variants of adiponectin (ADIPOQ) and cancer susceptibility: a meta-analysis. Genet Test Mol Biomarkers, 2014, 18(6): 417-424.